The US FDA's Endocrinologic and Metabolic Drugs Advisory Committee showed a degree of faith in the surrogate endpoint of percent change in fasting triglyceride (TG) at three months for Akcea Therapeutics Inc.'s Waylivra (volanesorsen) with a 12 to 8 vote in favor of approval for the treatment of familial chylomicronemia syndrome (FCS).
Panelists who voted "yes" during the May 10 meeting generally felt that the surrogate would correlate to clinical outcomes of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?